These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37271529)

  • 21. Plasma derivatives: new products and new approaches.
    Sauna ZE; Pandey GS; Jain N; Mahmood I; Kimchi-Sarfaty C; Golding B
    Biologicals; 2012 May; 40(3):191-5. PubMed ID: 22239993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current and Future Options of Haemophilia A Treatments.
    Miesbach W; Eladly F
    Expert Opin Biol Ther; 2021 Nov; 21(11):1395-1402. PubMed ID: 33769892
    [No Abstract]   [Full Text] [Related]  

  • 23. Pioneering designs for recombinant coagulation factors.
    Schulte S
    Thromb Res; 2011; 128 Suppl 1():S9-12. PubMed ID: 22221848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Current developments in hemostatic treatment for patients with hemophilia].
    Nogami K
    Rinsho Ketsueki; 2021; 62(8):1213-1221. PubMed ID: 34497209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simoctocog alfa for the treatment of hemophilia A.
    Morfini M
    Expert Opin Biol Ther; 2017 Dec; 17(12):1573-1580. PubMed ID: 29050497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand's disease: a systematic review of prospective studies.
    Franchini M; Makris M; Santagostino E; Coppola A; Mannucci PM
    Haemophilia; 2012 May; 18(3):e164-72. PubMed ID: 22250981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Unsolved issues of treatment of adult patients with hemophilia A].
    Zozulya NI; Dimitrieva OS
    Ter Arkh; 2022 Jan; 94(1):77-82. PubMed ID: 36286921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hemophilia therapy: the future has begun.
    Mannucci PM
    Haematologica; 2020 Mar; 105(3):545-553. PubMed ID: 32060150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The safety of pharmacologic options for the treatment of persons with hemophilia.
    Franchini M; Mannucci PM
    Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in hemophilia and the role of current and emerging prophylaxis.
    Acharya SS
    Am J Manag Care; 2016 Apr; 22(5 Suppl):s116-25. PubMed ID: 27266808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of haemophilia: From replacement to gene therapy.
    Páramo JA
    Med Clin (Barc); 2021 Dec; 157(12):583-587. PubMed ID: 34509300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of hemophilia with immunologic inhibitor of factor VIII by using "activated" coagulant fractions].
    Sultan Y; Brouet JC
    Nouv Presse Med; 1975 Oct; 4(36):2571-4. PubMed ID: 1081682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune complications and their management in inherited and acquired bleeding disorders.
    Arruda VR; Lillicrap D; Herzog RW
    Blood; 2022 Sep; 140(10):1075-1085. PubMed ID: 35793465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice.
    Sarafanov AG
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lasting power of new clotting proteins.
    Powell JS
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):355-63. PubMed ID: 25696879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful immune tolerance induction with low-dose coagulation factor VIII in a patient with hemophilia A from a developing country.
    Ay Y; Ersin T; Yesim O; Hilkay KT; Dilek I; Gulcihan O; Ahmet K
    Blood Coagul Fibrinolysis; 2016 Sep; 27(6):729-31. PubMed ID: 26484639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks.
    Castaman G; Linari S
    Expert Rev Hematol; 2018 Jul; 11(7):567-576. PubMed ID: 29886751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy.
    Kumar R; Dunn A; Carcao M
    Semin Thromb Hemost; 2016 Feb; 42(1):18-29. PubMed ID: 26771678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of prothrombin complex concentrates in the treatment of hemophiliacs with factor VIII inhibitors.
    Lusher JM
    Scand J Haematol Suppl; 1984; 40():195-202. PubMed ID: 6433452
    [No Abstract]   [Full Text] [Related]  

  • 40. Extended Half-Life Coagulation Factors: A New Era in the Management of Hemophilia Patients.
    Ar MC; Balkan C; Kavaklı K
    Turk J Haematol; 2019 Aug; 36(3):141-154. PubMed ID: 31088040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.